ArticleProceedings of the National Academy of Sciences of the United States of America2026

Next-generation anti-DLL3 radiopharmaceuticals targeting high-grade neuroendocrine lung and prostate cancers.

Salomon Tendler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.